Skip to content
Terminus Peptides
Sign inContact
  • Research use only — not for human or veterinary use
  • 67 compound profiles, every source cited
  • 63 research materials listed
  • Prices published, not hidden behind an enquiry
  • Vials and pre-filled pens
  • Dispatched and supported from the UK
  • Every profile states its UK regulatory status

Research profile · Biological material

Exosome-related material

Also known as UC-MSC exosome preparation, Extracellular vesicle preparation

Animal — evidence level 2 of 4: Animal evidenceUnlicensed — UK regulatory status: Unlicensed medicinal product (UK)

Overview

Extracellular vesicle preparations derived from cultured cells. No exosome product holds a marketing authorisation in the UK or elsewhere.

Category
Biological material
Highest evidence level identified
Animal evidence
Last scientifically reviewed
22 August 2026
Last regulatory review
22 August 2026

Mechanism under investigation

Exosomes are membrane vesicles of roughly 40–160 nanometres released by most cell types through the endosomal pathway, carrying proteins, lipids and nucleic acids from their cell of origin. They function in intercellular communication, and vesicles from mesenchymal stromal cells are studied as potential carriers of that cell type’s signalling. What a given preparation actually contains depends entirely on the source cells, culture conditions and isolation method — which is why the field’s own consensus guidance, MISEV, insists on characterising each preparation rather than treating “exosomes” as one substance. A particle count is a concentration, not an identity.

Research areas

  • Extracellular vesicle biology

These are fields in which the compound has been investigated. Listing a field is not a statement that anything was demonstrated within it.

Current evidence

In-vitro evidence

Cells, tissues or biochemical systems outside a living organism.

A very large cell-biology literature on vesicle biogenesis, cargo and uptake, systematised by the MISEV minimal-information standards after the field recognised how much published work was not comparable.

Animal evidence

Studies in living non-human animals.

Extensive preclinical work reports effects of MSC-derived vesicle preparations across injury models, with the recurring caveat that preparations differ between laboratories and doses are not standardised.

Human observational evidence

Studies observing people without assigning an intervention.

Diagnostic and biomarker work is substantial. For administered exosome products the human record is early trials and case reports — including, on the adverse side, serious events in the United States from unapproved products, which drew formal regulator warnings.

Clinical-trial evidence

Studies assigning an intervention to human participants.

Early-phase trials of specific, characterised preparations exist in defined indications. No exosome product has completed the development needed for a marketing authorisation anywhere, and results from one preparation cannot be read across to another because the products are not the same substance.

Study limitations

  • Preparation-dependence is the field’s defining limitation: source cells, culture, isolation and storage all change what the vesicles are and carry.
  • Commercial particle counts do not establish identity, purity or potency, and the MISEV standards exist because such figures are not comparable between products.
  • The administered-product literature is early-phase, heterogeneous and unreplicated; the strongest human data are diagnostic rather than therapeutic.
  • Serious adverse events from unapproved exosome products are documented, and no controlled safety dataset exists for any research-market preparation.

UK regulatory context

Unlicensed medicinal product (UK)

A product meeting the definition of a medicinal product but holding no UK marketing authorisation.

Source: The Human Medicines Regulations 2012, regulation 46 — prohibition on sale or supply of an unauthorised medicinal product (opens legislation.gov.uk in a new tab) (legislation.gov.uk)

Regulatory classification is jurisdiction-specific. A compound authorised elsewhere is not thereby authorised in the UK, and a supplier’s description of a substance does not determine how it is classified in law. See safety and regulation for the framework and the authoritative sources.

Safety and interpretation

No exosome product holds a marketing authorisation in the UK or in any comparable jurisdiction, so any exosome preparation presented for administration to people is an unauthorised medicinal — and as a cell-derived biological, one whose sterility, identity and content cannot be assumed from a label. United States regulators have publicly warned about serious adverse events from unapproved exosome products. This material is supplied, where it is supplied at all, strictly as laboratory research material; nothing about any preparation on the research market carries a safety dataset for use in people.